FemTech is moving from tracking apps to clinically validated, decentralized care. For instance, in May 2024, the US FDA expanded approvals for two human papillomavirus (HPV) screening tests, BD’s Onclarity HPV and Roche’s cobas HPV.

The decision allowed patient self-collection of vaginal samples in healthcare settings such as primary care offices, urgent care centers, pharmacies, and mobile clinics. Cervical cancer prevention requires scalable workflows that address access points, logistics, and follow-up, not just improved testing.

Further, capital is beginning to align with this clinical and distribution pivot, though investment remains limited relative to broader digital health. Global FemTech funding reached USD 2.2 billion in 2024, representing 8.5% of total digital health investment.

The next wave of FemTech companies will focus on integrating regulated diagnostics and evidence-backed services into real-world channels. These include pharmacy protocols, telehealth triage, lab integrations, and health-system partnerships.

Explore Innovations Shaping the FemTech Ecosystem

 

 

Diagnostic Intelligence as the Real Breakthrough

The World Health Organization estimates that about 190 million women and girls globally live with endometriosis. In the United States, the annual economic burden of endometriosis is estimated at USD 78-119 billion. This also combines healthcare expenditure and productivity losses.

There is growing investment in AI-enabled triage systems, biomarker panels, and non-invasive diagnostics to shorten diagnostic timelines. The US FDA has authorized more than 1300 AI and ML-enabled medical devices since 1995. Also, the approvals have accelerated in recent years.

In the United Kingdom, the government-backed Early Detection using Information Technology in Health (EDITH) trial is evaluating AI-assisted breast cancer screening across about 700 000 women. It is supported by GBP 11 million in funding via the National Institute for Health and Care Research (NIHR).

Moreover, AI-enhanced fetal ultrasound, cervical screening image analysis, and real-time scan quality detection reduce missed findings and operator variability.

Care Orchestration & Longitudinal Management

Women’s health conditions often require multi-year management rather than episodic care. Fertility, postpartum recovery, endometriosis, and menopause intersect with primary care, mental health, and specialty services.

Workforce shortages increase the need for orchestration platforms. The Royal College of Radiologists reports a 29% shortfall in consultant clinical radiologists in the UK. In the United States, projections anticipate a shortage of 5000 OB-GYNs by 2030.

These constraints create structural demand for remote monitoring, automated triage, and integrated digital pathways.

Also, pelvic floor biofeedback combined with guided training for urinary incontinence represents a growing care-at-home pathway in FemTech. It reduces clinic dependence for long-duration care plans that often extend across several months.

Shifting therapy into home settings gives patients flexibility while maintaining structured treatment. Providers are able to monitor progress remotely and adjust guidance as needed.

Alongside, US-based Teal Health is developing an at-home cervical cancer screening workflow using its Teal Wand for self-collection paired with telehealth, and it is FDA-approved.

Women’s Health Data Systems

Women’s health data remains fragmented across consumer applications and regulated clinical systems. The McKinsey Health Institute reports that half of the widely used interventions lack sex-disaggregated data. 64% women are disadvantaged in either efficacy or access among those studied.

 

 

Trust directly shapes adoption. The US Federal Trade Commission settled allegations that Flo Health shared sensitive user data with third parties after promising privacy.

Privacy governance is therefore foundational to enterprise-scale FemTech models. It determines whether platforms scale responsibly and sustain confidence among both patients and providers.

Innovations, like on-device processing, allow keeping inference and sensitive records on the phone or watch to reduce cloud exposure and third-party access paths. Further, zero-knowledge designing systems ensures vendor can not decrypt certain user data, especially journals, cycle events, and pregnancy outcomes.

Key Innovators Advancing FemTech

CleoCare creates a Breast Health Medical Device

Portuguese startup CleoCare makes SenseGlove, a home-based medical device to support breast self-examination and tissue monitoring for early detection of abnormalities.

The device leverages a sensor-equipped glove paired with a mobile app. The app guides users in performing a structured scan, records tactile data, and analyzes changes in breast tissue texture over time with embedded algorithms and physician-reviewed reports.

CleoCare reminds women to perform monthly checks, provides step-by-step instructions during the exam, and stores a history of results for comparison.

Further, professionals are able to review this data when needed. The device integrates data collection and reporting, which aids users in tracking patterns and sharing insights with healthcare providers

GyneCheck offers a Gynecological Self-Examination Platform

Israeli startup GyneCheck builds a remote gynecological self-exam platform for home use. It supports women in performing structured medical checks without clinic visits.

The startup combines a home exam device with a digital platform and guided interface. Users follow step-by-step protocols, collect health data, and connect with remote clinicians for review, input, and next-step guidance.

Moreover, the platform integrates physician guidance, structured data capture, and digital reporting. GyneCheck reduces reliance on in-clinic diagnostic procedures, supports ongoing monitoring of gynecological health, and promotes earlier detection of issues.

Embryoxite enables Non-Invasive Multimodal AI-powered Embryo Analysis

Argentinian startup Embryoxite develops an AI-driven fertility management and embryo assessment platform for IVF clinics and reproductive laboratories.

Its Nuvia IVF management system combines time-lapse embryo imaging, clinical biomarkers, and treatment data. The platform centralizes patient records, tracks IVF treatment stages, manages donors, and maintains traceability of cryopreserved embryos, oocytes, and sperm.

In addition, the startup applies machine learning models to generate predictive insights for embryo viability and ovarian reserve assessment using the OvAI system. It also provides personalized treatment recommendations based on parameters such as AMH and AFC.

Also, Embryoxite advances non-invasive analysis with the MetabScore kit, which focuses on rapid metabolic evaluation and simplified lab workflows without embryo manipulation.

ARTEMIS makes a Menstrual Pain Relief Body Suit

Hungarian startup ARTEMIS creates a bodysuit for menstrual pain management. It combines localized heat therapy with micro-vibration technology.

The embedded system applies controlled warmth and targeted vibrations to the lower abdominal area. It is operated by users via a connected mobile app.

The startup’s bodysuit delivers adjustable intensity levels, supports discreet daily wear, and integrates digital controls to personalize pain relief without medication.

This way, ARTEMIS aids in reducing menstrual discomfort during daily activities while maintaining a simple and repeatable usage routine.

Afynia Laboratories advances MicroRNA-based Molecular Screening for Endometriosis

Canadian startup Afynia Laboratories builds a blood-based diagnostic test for endometriosis using a panel of microRNA biomarkers. The test detects biological signals associated with the condition from a simple blood sample.

It isolates and quantifies specific microRNAs in the patient’s blood. Leveraging algorithms, these patterns are analyzed to distinguish profiles linked to endometriosis from those without the condition. This reduces reliance on invasive procedures like laparoscopy.

Also, the test involves a standard blood draw or potentially a finger-prick collection. It integrates with clinical workflows and provides objective information that supports physicians and patients in earlier decision-making.

Capital, Control & Power Centers in FemTech

FemTech capital flows are shifting from early-stage experimentation to consolidation around scaled platforms and incumbent acquirers.

Companies working on FemTech have raised USD 5.4 billion in venture capital since 2020 across more than 1000 global deals.

 

Credit: PitchBook

 

Silicon Valley Bank reports USD 2.6 billion invested in women’s health in 2024. That figure expands to USD 10.7 billion when including all conditions disproportionately affecting women.

Exit activity shows how control consolidates. Femtech exit value peaked in 2021 at USD 2.3 billion, then moderated to USD 0.8 billion in 2024, driven mainly by acquisitions rather than IPOs.

Hologic announced its acquisition of Gynesonics for about USD 350 million in October 2024. Also, Compass Diversified completed the acquisition of The Honey Pot Company at an enterprise value of USD 380 million in early 2024.

Late-stage capital is clustering around established platforms. For example, Flo Health raised more than USD 200 million in Series C funding in 2024. This pushed its valuation beyond USD 1 billion.

Maven Clinic also announced a USD 125 million Series F round in October 2024. It reached a valuation of USD 1.7 billion and serves over 2000 employer customers across 175 countries.

Public and philanthropic capital are also shaping the investment landscape. The US Advanced Research Projects Agency for Health committed more than USD 110 million across 23 teams under its Sprint for Women’s Health initiative in 2024. The Gates Foundation pledged USD 2.5 billion over five years for women’s health R&D.

Underserved FemTech Markets

Gynecological Pain & Chronic Conditions

A Nature review reports that US endometriosis research funding was USD 16 million in 2022. It represents only 0.038% of total NIH funding, or about USD 2 per patient per year.

This gap contrasts with the prevalence and productivity burden of the condition. It creates opportunity for diagnostics, non-invasive testing, and longitudinal management platforms that reduce time-to-diagnosis and downstream complications.

Menopause as an Economic White Space

Menopause remains one of the most underdeveloped segments within FemTech. Boston Consulting Group estimates that improved access to midlife hormonal care could expand the menopause treatment market to USD 40 billion by 2030.

In the United States, about 2 million women enter menopause each year. Yet only 60% of women with significant symptoms seek medical attention, and only 25% of those receive treatment.

RAND estimates that menopause symptoms contribute to USD 5.4 billion annually in lost productivity in the United States. Roughly 30% of women in the US labor force are aged 45-60.

 

Credit: RAND

 

Adolescent Health & Early Diagnostics

The World Health Organization reports that 30.7% of women aged 15-49 were affected by anemia in 2023, including 35.5% of pregnant women. In India, government data indicate that 59.1% of adolescent girls are anemic. These numbers underscore early-life health deficits that shape reproductive and maternal outcomes.

Early screening, adherence monitoring, and school-linked digital health infrastructure represent scalable intervention pathways in this segment.

Postpartum Physical & Mental Recovery

The World Health Organization estimates that about 13% of women globally experience a mental disorder after childbirth, rising to 19.8% in developing countries.

In the US, the CDC reports that 7.2% of women experience depressive symptoms 9-10 months postpartum. Notably, 57.4% of those cases were not present at earlier postpartum screenings, which indicates a delayed onset.

Methodology: Mapping the FemTech Landscape

We used the AI-powered StartUs Insights Discovery Platform to create this study. The platform tracks over 9M+ companies, 25K+ technologies and trends, alongwith 190M+ patents, news articles, and market reports to draw insights on the women’s health domain.

In this study, we focused on healthcare-grade FemTech infrastructure rather than consumer wellness applications. Our filtering included molecular diagnostics, AI-assisted imaging, IVF management systems, menopause therapeutics, pelvic health technologies, and employer-sponsored women’s health platforms.